February 15, 2018 / 3:15 PM / 3 days ago

BRIEF-Celgene Says Otezla Phase II Data Showed Clinically Meaningful Improvements In Active Ulcerative Colitis Patients

Feb 15 (Reuters) - Celgene Corp:

* OTEZLA® (APREMILAST) PHASE II DATA SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS

* CELGENE CORP - ‍PHASE III PROGRAM WITH OTEZLA (APREMILAST) IN ULCERATIVE COLITIS EXPECTED TO BEGIN IN 2018​

* CELGENE CORP - ‍PRIMARY ENDPOINT OF STUDY WAS TOTAL MAYO SCORE CLINICAL REMISSION AT WEEK 12 FOR 40 MG BID ARM​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below